|
|
|
|
LEADER |
01764 am a22002053u 4500 |
001 |
120750 |
042 |
|
|
|a dc
|
245 |
0 |
0 |
|a Accelerating biomedical innovation: a case study of the SPARK program at Stanford University, School of Medicine
|
260 |
|
|
|b Elsevier BV,
|c 2019-03-05T20:39:23Z.
|
856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/120750
|
520 |
|
|
|a Translating academic medical research into new therapies is an important challenge for the biopharmaceutical industry and investment communities, which have historically favored later-stage assets with lower risk and clearer commercial value. The Stanford SPARK program is an innovative model for addressing this challenge. The program was created in 2006 to educate students and faculty about bringing academic research from bench to bedside. Every year, the program provides mentorship and funding for approximately a dozen SPARK 'scholars,' with a focus on impacting patient lives, regardless of economic factors. By reviewing the detailed structure, function and operation of SPARK we hope to provide a template for other universities and institutions interested in de-risking and facilitating the translation of biomedical research.
|
655 |
7 |
|
|a Article
|
100 |
1 |
0 |
|a Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory
|e contributor
|
100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Chemical Engineering
|e contributor
|
100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science
|e contributor
|
100 |
1 |
0 |
|a Sloan School of Management
|e contributor
|
100 |
1 |
0 |
|a Kim, Esther
|e contributor
|
100 |
1 |
0 |
|a Omura, Paige M.
|e contributor
|
100 |
1 |
0 |
|a Lo, Andrew W
|e contributor
|
773 |
|
|
|t Drug Discovery Today
|